<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Cumberland-Pharmaceuticals-Inc-US2307701092">Cumberland Pharmaceuticals Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-strategic-transaction-to-integrate-commercial-business-with-apotex-302751769.html">Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex</a>
    </div>

      <div class="me-0 me-md-5">
        Transaction unlocks $100 million in value for Cumberland Sharpens focus on Orphan Drug Candidates to address Unmet Medical Needs NASHVILLE, Tenn., April 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. specialty pharmaceutical company, today announced it has entered into an agreement with an affiliate of Apotex (&quot;Apotex&quot;), the largest Canadian based pharmaceutical...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Cumberland-Pharmaceuticals-Inc-US2307701092">Cumberland Pharmaceuticals Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/redhills-opaganib-enhances-efficacy-of-neuroblastoma-chemo-combination-and-augment-anti-tumor-immunity-in-triple-negative-breast-cancer-in-preclinical-studies--new-data-presented-at-aacr-2026-302750239.html">RedHill&#39;s Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026</a>
    </div>

      <div class="me-0 me-md-5">
        New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects of opaganib [1] as potential add-on therapy in models of neuroblastoma (NB) and triple-negative breast cancer (TNBC) The positive NB data from studies undertaken by Penn State University&#39;s Jeremy Hengst and Apogee Biotechnology, and funde...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Cumberland-Pharmaceuticals-Inc-US2307701092">Cumberland Pharmaceuticals Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">5 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-expanded-indication-for-caldolor-ibuprofen-injection--and-launch-of-new-brand-website-302744319.html">CUMBERLAND PHARMACEUTICALS ANNOUNCES EXPANDED INDICATION FOR CALDOLOR® (IBUPROFEN) INJECTION AND LAUNCH OF NEW BRAND WEBSITE</a>
    </div>

      <div class="me-0 me-md-5">
        A Safe and Effective Non-Opioid Pain Management Solution NASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Cumberland-Pharmaceuticals-Inc-US2307701092/load_more?page=4">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>